Graves’ Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study
Main finding · Incident T2DResult — go to the resultHazard ratio 1.13 95% CI 1.06–1.21Authors' conclusion
Our findings highlight the negative impact of GD on the development of T2DM.
Study context
- Population
- Patients newly diagnosed with Graves' disease (GD) and age- and sex-matched controls, Korean National Health Insurance database; GD treated with antithyroid drug (ATDs) (96.2%), radioactive iodine therapy (RAIT) (3%) or surgery (0.8%)matched cohort
- Participants
- 36,243 vs 36,243
- Exposure
- GD vs matched controls
- GDn = 36,243
- Controlsn = 36,243reference
- Outcome
- Incident T2D
Methodological detailsmatched with age and sex, Korean National Health Insurance database
- Matched with age and sex
- Korean National Health Insurance database
Main finding
As reported in the abstract
Hazard ratio
1.13
95% CI 1.06–1.21
By group
GDvs Controls
HR 1.13 (95% CI 1.06–1.21)
Observational data: associations, not effects.
Further findings
| Outcome | HR |
|---|---|
| Incident T2D by time since GD diagnosisGD vs Controls · within first six months; highest risk | 3.21 |
| Incident T2D by time since GD diagnosisGD vs Controls · six months to two years; significant | 1.36 |
| Incident T2D by time since GD diagnosisGD vs Controls · after two years; comparable with controls | 0.93 |
ATD duration and cumulative dose
- Longer ATD treatment and higher cumulative dose associated with increased risk of diabetes
T2D risk by treatment modality or clinical outcomes
- Risks for T2D did not differ by treatment modality or clinical outcomes (small subgroups)
Original publication
Graves’ Disease and the Risk of Type 2 Diabetes: A Korean Population-Based Study. Thyroid. Published 20 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →